SAB Biotherapeutics Enhances Board With Medical Expert
Press Release: SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmac
SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : The SAB Biotherapeutics (SABS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $6.00.
HC Wainwright & Co. : The SAB Biotherapeutics (SABS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $6.00.
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics with a Buy and maintains $25 price target.
SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far
SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far
SAB Biotherapeutics Provides SAB-142 Trial Update
MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is
SAB Biotherapeutics Advances SAB-142 in Phase One Trials
SAB Biotherapeutics to Present at INNODIA Annual Meeting
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human
SAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy Rating
SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.
SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $6
HC Wainwright & Co. analyst Edward White maintains SAB Biotherapeutics with a Buy and lowers the price target from $10 to $6.
SAB Biotherapeutics GAAP EPS of -$7.64 Misses by $3.43, Revenue of $2.24M Beats by $1.12M
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed
SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline
SAB Biotherapeutics (SABS) said Monday that the Navy Medical Research Command will conduct a safety study of SAB-176, a potential treatment for influenza type A and B, as part of a research and develo
SAB Biotherapeutics Announces Clinical Partnership With Naval Medical Research Center to Advance Potential Influenza Treatment
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is
SAB Biotherapeutics Secures Leadership With New Executive Contracts
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing
No Data